Maj K. Kjeldsen

All identified pathogenic variants in the samples analyzed.

All identified pathogenic variants in the samples analyzed.

Oncoplot showing pathogenic gene alterations. The plot is split into groups by cellular pathways affected by the alteration on the vertical axis and clinical outcome (clinical benefit: PFS ≥12 months, no benefit: PFS ≤6 months) on the horizontal axis. Each column represents one patient. In total, 81 patient samples. See color guide reflecting specific alterations below the plot. # = Reason of “end of treatment” other than progressive disease. Integer “HRD-status and GIS” = the exact GIS reported by MyChoice.

Flowchart showing patients included in final gene panel analysis. * Formalin-fixed paraffin-embedded. ** TSO500 gene panel by Illumina.

BRCA1 (top) and BRCA2 (bottom) with variants found in AVANOVA1&2 colored by treatment response (see legend). BRCA1: Transcript NM_007294.4. In total, 1,863 aa. RING domain (aa 2–101), PALB2-binding domain (also called coiled-coil domain; aa 1,391–1,424), BRCT repeats (aa 1,650–1857), and exon 11 (aa 224–1,366). BRCA2: Transcript NM_000059.4. In total, 3,418 aa. PALB2-binding domain (aa 10–40), DNA-binding domain (aa 2,481–3,186), and exons 10 and 11 (aa 266–2,281).

Table 1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer

Best response in target lesions from baseline (RECIST 1.1-criteria). Dashed lines at +20% and −30% change from baseline equals stable disease. See guide in plot for color explanations.